{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:43:44Z","timestamp":1792593824784,"version":"4.5.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100020391","name":"Rhode Island Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020391","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,20]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>New SARS-CoV-2 variants arise frequently with different viral properties that can impact the effectiveness of the vaccines. Updating estimates of vaccine effectiveness (VE) in public health surveillance can be limited by the necessity of conducting a distinct study that entails analysis of prospective cohort data or using a test-negative design. We introduce a method for dynamically updating estimates of VE using data that accumulate in real time. Our method uses dynamic case-control sampling to estimate VE against a newly emerging variant relative to a previous variant. Dynamic case-control sampling is a technique that continuously updates VE estimates by comparing individuals infected with a newly emerging variant (defined as \u201ccases\u201d) to those infected with a previously circulating variant (defined as \u201ccontrols\u201d). We use this estimate in combination with information about VE from the previous variant (these estimates are typically available from larger, traditional studies) to infer VE against the emerging variant. We demonstrate the utility of this method on the BA.1 and BA.2 sub-lineages of the Omicron variant. The method produces estimates of VE comparable to those produced using traditional methods, although with increased SE. The increase in error, however, is reasonable given a much smaller sample size than other studies, and error ranges of the estimates could be significantly improved by sequencing a larger proportion of identified cases. Our method, which assumes only a fraction of the new cases are being sequenced, can be applied by health departments using routinely collected data to produce timely, rigorous VE estimates to rapidly identify potential changes in VE.<\/jats:p>","DOI":"10.1093\/biostatistics\/kxag002","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:49:07Z","timestamp":1772023747000},"source":"Crossref","is-referenced-by-count":0,"title":["Dynamic case-control sampling for rapid estimation of vaccine effectiveness against an emerging infectious disease variant"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9035-7649","authenticated-orcid":false,"given":"Taylor M","family":"Fortnam","sequence":"first","affiliation":[{"name":"Department of Biostatistics, Brown University School of Public Health , 121 S Main St , Providence, RI 02903,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C","family":"Chambers","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Brown University School of Public Health , 121 S Main St , Providence, RI 02903,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Bilinski","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Brown University School of Public Health , 121 S Main St , Providence, RI 02903,","place":["United States"]},{"name":"Department of Health Services, Policy, and Practice, Brown University School of Public Health , 121 S Main St , Providence, RI 02903,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"King","sequence":"additional","affiliation":[{"name":"Rhode Island Department of Health , 3 Capitol Hill , Providence, RI 02908,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C","family":"Huard","sequence":"additional","affiliation":[{"name":"Rhode Island Department of Health , 3 Capitol Hill , Providence, RI 02908,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Amore","sequence":"additional","affiliation":[{"name":"Rhode Island Department of Health , 3 Capitol Hill , Providence, RI 02908,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M","family":"Gargano","sequence":"additional","affiliation":[{"name":"Rhode Island Department of Health , 3 Capitol Hill , Providence, RI 02908,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"McDonald","sequence":"additional","affiliation":[{"name":"Rhode Island Department of Health , 3 Capitol Hill , Providence, RI 02908,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brown University , 222 Richmond St , Providence, RI 02903,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W","family":"Hogan","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Brown University School of Public Health , 121 S Main St , Providence, RI 02903,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"2026102110221903000_kxag002-B1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1056\/NEJMc2104974","article-title":"Effectiveness of the BNT162b2 COVID-19 vaccine against the B.1.1.7 and B.1.351 variants","volume":"385","author":"Abu-Raddad","year":"2021","journal-title":"N Engl J Med"},{"key":"2026102110221903000_kxag002-B2","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"COVID-19 vaccine effectiveness against the Omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"2026102110221903000_kxag002-B3","doi-asserted-by":"publisher","first-page":"e068848","DOI":"10.1136\/bmj-2021-068848","article-title":"Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants of SARS-CoV-2: test negative case-control study","volume":"375","author":"Bruxvoort","year":"2021","journal-title":"BMJ"},{"key":"2026102110221903000_kxag002-B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.32760"},{"key":"2026102110221903000_kxag002-B5","volume-title":"COVID data tracker","author":"Centers for Disease Control and Prevention","year":"2024"},{"key":"2026102110221903000_kxag002-B6","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1038\/s41467-022-30895-3","article-title":"Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA. 2 subvariants in Qatar","volume":"13","author":"Chemaitelly","year":"2022","journal-title":"Nat Commun"},{"key":"2026102110221903000_kxag002-B7","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMc2119270","article-title":"Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa","volume":"386","author":"Collie","year":"2022","journal-title":"N Engl J Med"},{"key":"2026102110221903000_kxag002-B8","doi-asserted-by":"publisher","first-page":"2101196","DOI":"10.2807\/1560-7917.ES.2022.27.4.2101196","article-title":"Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, The Netherlands, 22 November 2021 to 19 January 2022","volume":"27","author":"Eggink","year":"2022","journal-title":"Euro Surveill"},{"key":"2026102110221903000_kxag002-B9","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/ije\/22.4.742","article-title":"Estimation of vaccine effectiveness using the screening method","volume":"22","author":"Farrington","year":"1993","journal-title":"Int J Epidemiol"},{"key":"2026102110221903000_kxag002-B10","doi-asserted-by":"publisher","first-page":"e1003992","DOI":"10.1371\/journal.pmed.1003992","article-title":"Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: a nationwide Danish cohort study","volume":"19","author":"Gram","year":"2022","journal-title":"PLoS Med"},{"key":"2026102110221903000_kxag002-B11","first-page":"18","article-title":"Optmatch: flexible, optimal matching for observational studies","volume":"7","author":"Hansen","year":"2007","journal-title":"New Funct Multivariate Anal"},{"key":"2026102110221903000_kxag002-B12","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.20.21267966","article-title":"Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study (Version 3).","author":"Hansen","year":"2021","journal-title":"medRxiv"},{"key":"2026102110221903000_kxag002-B13","doi-asserted-by":"publisher","first-page":"5706","DOI":"10.1038\/s41467-022-33233-9","article-title":"Increased household transmission and immune escape of the SARS-CoV-2 Omicron compared to Delta variants","volume":"13","author":"Jalali","year":"2022","journal-title":"Nat Commun"},{"key":"2026102110221903000_kxag002-B14","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3201\/eid2407.180028","article-title":"Mapping of the us domestic influenza virologic surveillance landscape","volume":"24","author":"Jester","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"2026102110221903000_kxag002-B15","doi-asserted-by":"crossref","first-page":"e5079","DOI":"10.1371\/journal.pone.0005079","article-title":"Estimation of influenza vaccine effectiveness from routine surveillance data","volume":"4","author":"Kelly","year":"2009","journal-title":"PLoS One"},{"key":"2026102110221903000_kxag002-B16","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1473-3099(22)00309-7","article-title":"COVID-19 vaccine effectiveness against the omicron (BA. 2) variant in England","volume":"22","author":"Kirsebom","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2026102110221903000_kxag002-B17","doi-asserted-by":"crossref","first-page":"e069761","DOI":"10.1136\/bmj-2021-069761","article-title":"Clinical severity of, and effectiveness of mRNA vaccines against, COVID-19 from Omicron, Delta, and Alpha SARS-CoV-2 variants in the United States: prospective observational study","volume":"376","author":"Lauring","year":"2022","journal-title":"BMJ"},{"key":"2026102110221903000_kxag002-B18","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1056\/NEJMc2209371","article-title":"Effects of vaccination and previous infection on Omicron infections in children","volume":"387","author":"Lin","year":"2022","journal-title":"N Engl J Med"},{"key":"2026102110221903000_kxag002-B19","doi-asserted-by":"crossref","first-page":"e232598","DOI":"10.1001\/jamanetworkopen.2023.2598","article-title":"Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and severity by vaccination status during Omicron BA.4 and BA.5 sublineage periods","volume":"6","author":"Link-Gelles","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026102110221903000_kxag002-B20","doi-asserted-by":"publisher","first-page":"e822","DOI":"10.1093\/cid\/ciab1041","article-title":"Neutralization of severe acute respiratory syndrome coronavirus 2 omicron variant by sera from BNT162b2 or CoronaVac vaccine recipients","volume":"75","author":"Lu","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026102110221903000_kxag002-B21","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/s41467-024-46536-w","article-title":"Quantifying how single dose ad26. cov2. s vaccine efficacy depends on spike sequence features","volume":"15","author":"Magaret","year":"2024","journal-title":"Nat Commun"},{"key":"2026102110221903000_kxag002-B22","doi-asserted-by":"publisher","first-page":"R918","DOI":"10.1016\/j.cub.2021.06.049","article-title":"The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic","volume":"31","author":"Otto","year":"2021","journal-title":"Curr Biol"},{"key":"2026102110221903000_kxag002-B23","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.15585\/mmwr.mm7050e1","article-title":"SARS-CoV-2 B.1.1.529 (Omicron) variant \u2013 United States, December 1\u20138, 2021","volume":"70","author":"Perrine","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026102110221903000_kxag002-B24","author":"Puranik","year":"2021"},{"key":"2026102110221903000_kxag002-B25","doi-asserted-by":"publisher","first-page":"106261","DOI":"10.1016\/j.ijsu.2022.106261","article-title":"The Omicron subvariant BA.2: birth of a new challenge during the COVID-19 pandemic","volume":"99","author":"Rahimi","year":"2022","journal-title":"Int J Surg"},{"key":"2026102110221903000_kxag002-B26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1056\/NEJMoa2116063","article-title":"COVID-19 vaccine effectiveness in New York State","volume":"386","author":"Rosenberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2026102110221903000_kxag002-B27","doi-asserted-by":"publisher","first-page":"2100793","DOI":"10.2807\/1560-7917.ES.2021.26.35.2100793","article-title":"Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021","volume":"26","author":"Sepp\u00e4l\u00e4","year":"2021","journal-title":"Euro Surveill"},{"key":"2026102110221903000_kxag002-B28","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/infdis\/jiac161","article-title":"Protection by vaccines and previous infection against the Omicron variant of severe acute respiratory syndrome coronavirus 2","volume":"226","author":"\u0160m\u00edd","year":"2022","journal-title":"J Infect Dis"},{"key":"2026102110221903000_kxag002-B29","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.ekir.2022.04.005","article-title":"Comparison of vaccine effectiveness against the Omicron (B. 1.1. 529) variant in hemodialysis patients","volume":"7","author":"Spensley","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"8","key":"2026102110221903000_kxag002-B30","first-page":"1","article-title":"Matchit: Nonparametric preprocessing for parametric causal inference","volume":"42","author":"Stuart","year":"2011","journal-title":"J Stat Softw"},{"key":"2026102110221903000_kxag002-B31","doi-asserted-by":"publisher","first-page":"100198","DOI":"10.1016\/j.lana.2022.100198","article-title":"Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: a retrospective cohort study","volume":"9","author":"Tartof","year":"2022","journal-title":"Lancet Regional Health Am"},{"key":"2026102110221903000_kxag002-B32","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41591-022-01753-y","article-title":"Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants","volume":"28","author":"Tseng","year":"2022","journal-title":"Nat Med"},{"key":"2026102110221903000_kxag002-B33","author":"van der Laan","year":"2025"},{"key":"2026102110221903000_kxag002-B34","doi-asserted-by":"crossref","first-page":"104158","DOI":"10.1016\/j.ebiom.2022.104158","article-title":"Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA. 1 and BA. 2 by convalescent and vaccine serum and monoclonal antibodies","volume":"82","author":"Wilhelm","year":"2022","journal-title":"EBioMedicine"},{"key":"2026102110221903000_kxag002-B35","author":"World Health Organization","year":"2021"},{"key":"2026102110221903000_kxag002-B36","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMc2201849","article-title":"Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 variants","volume":"386","author":"Yu","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Biostatistics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/biostatistics\/article-pdf\/27\/1\/kxag002\/68053542\/kxag002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/biostatistics\/article-pdf\/27\/1\/kxag002\/68053542\/kxag002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:22:24Z","timestamp":1792592544000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/biostatistics\/article\/doi\/10.1093\/biostatistics\/kxag002\/8652929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,20]]}},"URL":"https:\/\/doi.org\/10.1093\/biostatistics\/kxag002","relation":{},"ISSN":["1465-4644","1468-4357"],"issn-type":[{"value":"1465-4644","type":"print"},{"value":"1468-4357","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"kxag002"}}